On this page
ERF
ETS2 repressor factor
ERF encodes ETS2 repressor factor, a transcriptional repressor of ETS-family target genes in the MAPK signalling pathway. Heterozygous ERF variants cause autosomal dominant craniosynostosis type 4, typically involving multiple sutures with variable intellectual outcomes and Chiari I malformation risk.
ERF is located on the long (q) arm of chromosome 19, at band 19q13.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 19 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The ERF gene, located on chromosome 19, encodes ETS2 repressor factor, a transcriptional regulator belonging to the ETS family of DNA-binding proteins. This protein plays a critical role during embryonic development, particularly in regulating the timing of bone formation in the skull. ERF functions primarily as a repressor, switching off specific genes at precise developmental stages to ensure proper skeletal patterning.
Pathogenic variants in ERF disrupt normal transcriptional control, leading to craniosynostosis syndromes where one or more skull sutures fuse prematurely. These conditions can affect skull shape and, in some cases, brain development. ERF-related craniosynostosis is inherited in an autosomal dominant manner, meaning a pathogenic variant in one copy of the gene is sufficient to cause features of the condition. The gene is recognised on four NHS Genomic Medicine Service (England) panels covering craniosynostosis and skeletal dysplasia, and is included in the DDG2P database of established developmental disorder genes.
What the gene does
ERF acts as a transcriptional repressor, binding to specific DNA sequences to prevent gene activation. The protein recognises ETS-binding motifs in regulatory regions of target genes, particularly those involved in skeletal development and cell proliferation pathways. By occupying these sites, ERF blocks the activity of transcriptional activators, effectively silencing genes that would otherwise promote bone formation or cell division.
During skull development, ERF helps maintain the open sutures between cranial bones by repressing genes that drive premature ossification. This regulatory function is essential for normal skull growth, allowing the brain to expand during infancy and early childhood. The protein's activity must be precisely calibrated, as both excessive and insufficient repression can disrupt the delicate balance between bone growth and suture maintenance.
ERF also participates in broader developmental signalling networks, including pathways regulated by fibroblast growth factors. Through its repressor activity, ERF modulates cellular responses to growth signals, ensuring that proliferation and differentiation occur at appropriate times and locations. This coordination is particularly important in tissues undergoing rapid morphological change during embryogenesis.
Video: Genetics 101
Chromosome location
ERF is positioned at chromosomal location 19q13.2, within the long arm of chromosome 19. This region contains numerous genes involved in diverse biological processes. The gene spans approximately 24 kilobases of genomic DNA and contains several exons that are spliced together to produce the mature messenger RNA template for protein synthesis.
The 19q13.2 region is generally stable in the human genome, though like all chromosomal locations it can be affected by structural rearrangements. The precise positioning of ERF within this band has been mapped through genomic sequencing projects, providing a reference for clinical variant interpretation and diagnostic testing.
Protein structure
The ERF protein comprises 548 amino acids organised into distinct functional and structural regions. The N-terminal portion contains the ETS DNA-binding domain spanning amino acids 27 to 108, which mediates sequence-specific recognition of target gene promoters and enhancers. This domain adopts a characteristic winged helix-turn-helix fold that inserts into the major groove of DNA, making base-specific contacts with ETS motifs.
Much of the ERF protein consists of intrinsically disordered regions that lack fixed three-dimensional structure in isolation. Rather than being non-functional, these flexible regions likely mediate protein-protein interactions and provide regulatory flexibility, allowing ERF to respond dynamically to cellular signals. Disordered regions in transcription factors often serve as interaction platforms for co-repressor complexes and post-translational modification sites that modulate activity.
Key variants
Pathogenic variants are frequently found within or near the ETS DNA-binding domain, though changes throughout the gene have been reported in individuals with craniosynostosis. Loss-of-function variants, including nonsense and frameshift changes that truncate the protein, are a common mechanism. These alterations reduce the amount of functional ERF available to repress target genes, leading to inappropriate activation of bone formation pathways.
Missense variants that alter single amino acids can disrupt DNA binding or protein stability, depending on their location. Changes within the ETS domain may prevent ERF from recognising its target sequences, while variants in other regions might affect interactions with regulatory partners. The autosomal dominant inheritance pattern means that haploinsufficiency (where one working gene copy cannot produce enough protein) is the primary disease mechanism for most ERF-related conditions.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1072_1073del | p.Pro358fs | Pathogenic/Likely pathogenic | ★★☆☆ | TWIST1-related craniosynostosis |
c.1201_1202del | p.Lys401fs | Pathogenic/Likely pathogenic | ★★☆☆ | Noonan-like syndrome |
c.256C>T | p.Arg86Cys | Pathogenic/Likely pathogenic | ★★☆☆ | Lambdoidal craniosynostosis |
c.266A>G | p.Tyr89Cys | Pathogenic | ★★☆☆ | Chitayat syndrome |
c.427del | p.Arg143fs | Pathogenic/Likely pathogenic | ★★☆☆ | Inborn genetic diseases |
c.547C>T | p.Arg183Ter | Pathogenic | ★★☆☆ | Lambdoidal craniosynostosis |
c.566_567del | p.Asp188_Cys189insTer | Pathogenic | ★★☆☆ | Lambdoidal craniosynostosis |
c.619C>T | p.Arg207Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Noonan Syndrome-like developmental disorder |
c.652C>T | p.Arg218Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Noonan Syndrome-like developmental disorder |
c.697C>T | p.Arg233Ter | Pathogenic | ★★☆☆ | Noonan Syndrome-like developmental disorder |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic ERF variants cause craniosynostosis syndromes characterised by premature fusion of cranial sutures. The clinical presentation varies among affected individuals, ranging from single-suture synostosis to more complex patterns involving multiple sutures. Craniosynostosis can lead to abnormal skull shape and, if severe or untreated, may result in increased intracranial pressure affecting brain development.
Some individuals with ERF variants also present with additional skeletal features beyond craniosynostosis, including characteristic facial features and limb abnormalities. The severity and specific combination of features can differ even within the same family, reflecting variable expressivity common in autosomal dominant conditions. Early diagnosis through genetic testing enables appropriate surgical planning and monitoring for developmental concerns.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic ERF variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
ERF holds green (high-evidence) status on four NHS Genomic Medicine Service panels, reflecting strong clinical validity for genetic testing in specific contexts. The gene appears on the Common craniosynostosis syndromes panel (R99) and the Rare syndromic craniosynostosis or isolated multisuture synostosis panel (R100), both core to diagnosing ERF-related conditions. Additional green ratings on the Skeletal dysplasia panel (R104) and Fetal anomalies panel (R21) recognise ERF's role in prenatal and paediatric skeletal presentations.
Inclusion on the DDG2P (Developmental Disorders Genotype-to-Phenotype) database further confirms ERF as an established developmental disorder gene. This NHS panel membership means that ERF testing is available through the Genomic Medicine Service when clinical features align with panel indications, supported by genetic counselling and multidisciplinary clinical review.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with ERF-related craniosynostosis, lifestyle considerations centre on supporting overall bone health and development rather than modifying gene function directly. Research in skeletal development suggests that adequate nutrition during growth periods supports bone remodelling and healing following surgical intervention, though no specific dietary pattern has been shown to prevent or reverse craniosynostosis itself.
Calcium and vitamin D are essential for bone metabolism in the general population, and ensuring sufficient intake may support skeletal health in children undergoing craniofacial surgery. Some studies in broader skeletal conditions indicate that physical activity appropriate to developmental stage promotes bone strength, though specific exercise recommendations for craniosynostosis patients should be discussed with clinical teams familiar with the individual's surgical history and skull structure.
Supplement considerations
There is no evidence that dietary supplements can prevent craniosynostosis or modify outcomes in individuals with ERF variants. While calcium and vitamin D supplementation may be recommended by healthcare providers to support general bone health, particularly in children with restricted dietary intake or limited sun exposure, these nutrients do not address the underlying transcriptional dysregulation caused by ERF variants.
Any supplement use should be discussed with a healthcare provider, as excessive intake of certain nutrients can have adverse effects. For individuals with craniosynostosis, decisions about supplementation should be integrated into broader clinical management plans that consider surgical interventions, developmental monitoring, and individual nutritional status.
Frequently asked questions
How is ERF-related craniosynostosis inherited?
ERF-related craniosynostosis follows an autosomal dominant pattern, meaning a pathogenic variant in one copy of the gene is sufficient to cause the condition. An affected parent has a 50% chance of passing the variant to each child, though some cases arise from new variants not inherited from either parent.
What does the ERF protein do in normal development?
ERF functions as a transcriptional repressor that prevents premature activation of genes involved in bone formation. During skull development, ERF helps maintain open sutures between cranial bones by blocking genes that would otherwise trigger early fusion, allowing normal brain growth.
Can genetic testing for ERF be accessed through the NHS?
Yes, ERF testing is available through the NHS Genomic Medicine Service for individuals meeting clinical criteria on relevant panels, including craniosynostosis and skeletal dysplasia indications. Referral through appropriate clinical services and genetic counselling support are part of the testing pathway.
Do all ERF variants cause the same severity of craniosynostosis?
No, ERF-related craniosynostosis shows variable expressivity, with different individuals experiencing different patterns of suture fusion and associated features. Even within the same family carrying the same variant, clinical severity can differ, reflecting the complex interplay of genetic and developmental factors.
Are there treatments for ERF-related craniosynostosis?
Management typically involves surgical intervention to release fused sutures and reshape the skull, allowing normal brain growth. Treatment plans are individualised based on which sutures are affected, the child's age, and developmental needs, coordinated through specialist craniofacial teams.